Viking Therapeutics, Inc. — Company profile
Healthcare · Biotechnology · United States
Last price 26.86 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 3.43B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. The company develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, which is in Phase II clinical trials for metabolic disorders and anemia; VK2735, a novel dual agonist of the glucagon-like peptide 1, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.
Details
| Name | Viking Therapeutics, Inc. |
| Sector | Healthcare |
| Industry | Biotechnology |
| Employees | 65 |
| Founded | 2012 |
| Ipo Date | 2015-04-29 |
| Ceo | Brian Lian |
| Country | United States |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Isin | US92686J1060 |
| Cusip | 92686J106 |
| Cik | 0001607678 |
| Sic | 2834 |
| Stock Type | Common Stock |
Key executives
| Name | Title |
|---|---|
| Dr. Brian Lian Ph.D. | President, Chief Executive Officer and Director |
| Gregory S. Zante CPA | Chief Financial Officer |
| Michael Morneau | Vice President of Finance and Administration |
| Katherine Mercier | Vice President of Quality and Compliance |
| Kenneth J. Herman M.B.A. | Senior Vice President of Commercial, Marketing and Sales |
| Dr. Geoffrey E. Barker Ph.D. | Chief Development Officer |
| Dr. Nils U. Olsson Ph.D. | Senior Vice President of Technical Operations |
| Dr. Hubert C. Chen M.D., M.P.H. | Chief Medical Officer |
Contact
| Address | 9920 Pacific Heights Boulevard, Suite 350, San Diego, California 92121, United States |
| Phone | 858 704 4660 |
| Website | https://www.vikingtherapeutics.com |